🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Robert Akpata

Université de Bordeaux

ORCID: 0000-0002-9628-8904

Also affiliated with Inserm, Bordeaux Population Health, Institut de Recherche pour le Développement

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile
0.341Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Tuberculosis Sentinel Research Network (TB-SRN) of the International epidemiology Databases to Evaluate AIDS (IeDEA): protocol for a prospective cohort study in Africa, Southeast Asia and Latin America

BMJ Open(2024)10.1136/bmjopen-2023-079138
Top 51%
0.341DataRank
Top 51%7 citations

Stephany N. Duda, Thida Chanyachukul, Carolyn Bolton‐Moore, Neelima Navuluri, Eugène Messou +24 more

Papers

Driven by 5 papers — median percentile 49. Top paper: “Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults”.

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Clinical Infectious Diseases(2023)10.1093/cid/ciad693
N/A
0.671DataRank · unranked
16 citations

Ken Liu, Édouard Lhomme, Julie Blie, John McCullough, Matthew Onorato +90 more

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

Trials(2021)10.1186/s13063-021-05035-9
N/A
0.630DataRank · unranked
18 citations

Édouard Lhomme, Mark Kieh, Abdoul Habib Béavogui, Stephen B. Kennedy, Seydou Doumbia +91 more

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

Nature Communications(2024)10.1038/s41467-024-51453-z
N/A
0.596DataRank · unranked
19 citations

Édouard Lhomme, Mélanie Huchon, Emile Foucat, Marion Bérerd-Camara, Lydia Guillaumat +94 more

The Tuberculosis Sentinel Research Network (TB-SRN) of the International epidemiology Databases to Evaluate AIDS (IeDEA): protocol for a prospective cohort study in Africa, Southeast Asia and Latin America

BMJ Open(2024)10.1136/bmjopen-2023-079138
Top 51%
0.341DataRank
Top 51%7 citations

Stephany N. Duda, Thida Chanyachukul, Carolyn Bolton‐Moore, Neelima Navuluri, Eugène Messou +24 more

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

Emerging Microbes & Infections(2024)10.1080/22221751.2024.2432353
N/A
0.251DataRank · unranked
4 citations

Marie Alexandre, Mélanie Prague, Abdoul Habib Béavogui, Seydou Doumbia, Mark Kieh +94 more